Clinical Research Directory
Browse clinical research sites, groups, and studies.
Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer
Sponsor: Sohag University
Summary
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival
Official title: Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2026-05-01
Completion Date
2026-07-01
Last Updated
2026-07-20
Healthy Volunteers
Not specified
Conditions
Interventions
Chemo-radiotherapy alone
Chemo and radiotherapy before surgery
Not applicable- observational study
Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.
Locations (1)
Sohag university
Sohag, Egypt